Science Explorer Back to mapMap
Discussion
Topic · Immunology

IL-33, ST2, and ILC Pathways

IL-33, ST2, and ILC Pathways is a research topic within Immunology. Science Explorer counts 17k research works in it since 1954. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers explores the role of innate lymphoid cells, particularly their interaction with IL-33, in regulating type 2 immunity, tissue homeostasis, mucosal immunity, allergic inflammation, and the interplay with the adaptive immune system. It also delves into their involvement in various inflammatory diseases and their influence on regulatory T cells.

  • Innate Lymphoid Cells
  • IL-33
  • Type 2 Immunity
  • Tissue Homeostasis
  • Interleukin-1 Family
  • Mucosal Immunity
  • Allergic Inflammation
  • Regulatory T Cells
  • Adaptive Immune System
  • Inflammatory Diseases
Research works
17k
fractional, since 1954
In the world top 10%
1.7k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+10%
the tick is no change
Largest producer
China
37% of the 10 largest, 2022-now
IL-33, ST2, and ILC Pathways

Which countries lead IL-33, ST2, and ILC Pathways research?

By volume, China and the United States publish the most (1.3k and 1.1k works in 2022-now).

By volume, 2022-now

  1. 1 China 1.3k works
  2. 2 United States 1.1k works
  3. 3 Japan 217 works
  4. 4 Germany 210 works
  5. 5 United Kingdom 190 works
  6. 6 Italy 149 works
  7. 7 France 125 works
  8. 8 South Korea 118 works
  9. 9 Canada 111 works
  10. 10 Spain 102 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 36.8%United States: 29.2%Japan: 6.0%Germany: 5.8%6 others listed: 22.1%37%largest
China1,322 · 36.8%United States1,051 · 29.2%Japan217 · 6.0%Germany210 · 5.8%6 others listed795 · 22.1%

Shares of the rows listed above, not of the whole node.

Which institutions lead IL-33, ST2, and ILC Pathways research?

By volume in 2022-now, Harvard University publishes the most IL-33, ST2, and ILC Pathways research, followed by Shanghai Jiao Tong University and Sun Yat-sen University.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 60 works
  2. 2 Shanghai Jiao Tong UniversityChina 40 works
  3. 3 Sun Yat-sen UniversityChina 33 works
  4. 4 Nanjing Medical UniversityChina 33 works
  5. 5 National Institutes of HealthUnited States 33 works
  6. 6 Capital Medical UniversityChina 33 works
  7. 7 Central South UniversityChina 29 works
  8. 8 Zhejiang UniversityChina 28 works
  9. 9 InsermFrance 27 works
  10. 10 Huazhong University of Science and TechnologyChina 27 works

Who are the leading researchers in IL-33, ST2, and ILC Pathways?

The most-cited researchers publishing on IL-33, ST2, and ILC Pathways include Eric S. Lander, Rob Knight and George Davey Smith.

  1. 1 Eric S. Lander United States 524k citations
  2. 2 Rob Knight United States 468k citations
  3. 3 George Davey Smith United Kingdom 435k citations
  4. 4 Mark J. Daly United States 403k citations
  5. 5 John J.V. McMurray United Kingdom 349k citations
  6. 6 Hermann Brenner Germany 343k citations
  7. 7 Shizuo Akira Japan 342k citations
  8. 8 Emelia J. Benjamin United States 341k citations
  9. 9 Jun Wang China 340k citations
  10. 10 Mika Kivimäki United Kingdom 318k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in IL-33, ST2, and ILC Pathways?

The most cited paper in IL-33, ST2, and ILC Pathways is "Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death" (Jianjin Shi, Yue Zhao, Kun Wang et al., 2015), with 6,817 citations. Next come "The Inflammasomes" (5,489) and "The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells" (5,186).

Most cited papers
#PaperReleasedCitations
1 Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death Jianjin Shi, Yue Zhao, Kun Wang et al. · Nature 16 Sep 2015 6,817
2 The Inflammasomes Kate Schroder, Jürg Tschopp · Cell Open access Mar 2010 5,489
3 The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells Ivaylo I. Ivanov, Brent S. McKenzie, Liang Zhou et al. · Cell Open access Sep 2006 5,186
4 Unravelling the pathogenesis of inflammatory bowel disease Ramnik J. Xavier, Daniel K. Podolsky · Nature Jul 2007 4,394
5 Interleukin-10-deficient mice develop chronic enterocolitis Ralf Kühn, Jürgen Löhler, Donna M. Rennick et al. · Cell Oct 1993 4,325
All 100 most cited papers, with filters and sorting

Where is IL-33, ST2, and ILC Pathways research done?

The largest centres of IL-33, ST2, and ILC Pathways research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and Wuhan (China). Among places with at least 20 works in it, it is an unusually large share of all research in Denver and Cincinnati.

Largest cities, 2022-now

  1. 1 BeijingChina 153 works
  2. 2 ShanghaiChina 118 works
  3. 3 GuangzhouChina 110 works
  4. 4 WuhanChina 64 works
  5. 5 LondonUnited Kingdom 63 works
  6. 6 ParisFrance 63 works
  7. 7 SeoulSouth Korea 61 works
  8. 8 NanjingChina 60 works
  9. 9 TokyoJapan 58 works
  10. 10 HangzhouChina 53 works

Where it is the local speciality

  1. DenverUS · 22.5 works7.7×
  2. CincinnatiUS · 21.5 works6.1×
← less than its size predicts1×more →

Location quotient: how much more of its research is in IL-33, ST2, and ILC Pathways than the world average.

See IL-33, ST2, and ILC Pathways on the map

Where is the best place to study IL-33, ST2, and ILC Pathways?

Among universities, judged by research, Harvard University, University of Pittsburgh and Cornell University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 16.59%fractional works in this field (log) →share of work in the world top 10% →Harvard UniversityCornell UniversityUniversity of Pittsb…Imperial College Lon…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 80.720.6%4.7×60 -6.9%
2University of PittsburghUnited States 64.916.1%6.8×22 +32.0%
3Cornell UniversityUnited States 62.720.6%3.4×18 -11.3%
4Imperial College LondonUnited Kingdom 60.013.1%5.0×20 +6.3%
5Shanghai Jiao Tong UniversityChina 59.513.4%3.4×40 +25.8%
6Southern Medical UniversityChina 58.515.0%9.1×23 +82.9%
7Washington University in St. LouisUnited States 57.216.3%7.2×21 -6.4%
8Chengdu University of Traditional Chinese MedicineChina 55.619.6%9.4×10 +495.2%
9Sun Yat-sen UniversityChina 55.313.1%4.0×33 +11.4%
10University of California, San FranciscoUnited States 54.318.1%4.3×12 -29.8%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in IL-33, ST2, and ILC Pathways, country by country

Is IL-33, ST2, and ILC Pathways research growing?

Output in 2022-2025 was 10% higher than in 2018-2021, peaking in 2022. The fastest-growing topics are IL-33, ST2, and ILC Pathways.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is IL-33, ST2, and ILC Pathways as a percentage of every work published that year, 0.018% in 2024.

still counting0.010%0.020%0.030%IL-33, ST2, and ILC Pathways0.018% in 202519801990200020102020

Fractional works of IL-33, ST2, and ILC Pathways over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%IL-33, ST2, and ILC Pathways10.0% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about IL-33, ST2, and ILC Pathways. Posts are plain text and can be reported.